A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
Sponsor: Daiichi Sankyo
This PHASE1 trial investigates Netherton Syndrome and is currently completed. Daiichi Sankyo leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2023 — Mar 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Dec 2022 — Apr 2023 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Oct 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Sep 2022 — Oct 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .